More News on Scenesse in Vitiligo

Clinuvel just announced today that the FDA has agreed to discuss and implement the North American development program for SCENESSE (afamelanotide 16mg) for the pigment loss disorder vitiligo. In a study done in the United States, it was shown that significant recovery of pigmentation was observed in patients with darker skin complexion (Fitzpatrick skin types IV-VI). This is wonderful news, and something we have all been waiting for since the medicine’s approval by the FDA in October 2019 to increase pain-free light exposure in adult patients with the rare metabolic disorder erythropoietic protoporphyria (EPP). April 29 is the date set for the discussion, and I will update you here as news becomes available.